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Background: Multiple sclerosis (MS) is the second largest cause of 
moderate/severe disabilities in individuals between 20-50 years of age. 
Spasticity is a common disabling symptom with a prevalence of up to 84%, 
mainly affecting the flexor muscles (upper extremities) and extensor muscles 
(lower extremities), which consequently produced alterations in walking 
pattern and functional capacity. 
Repetitive Transcranial Magnetic Stimulation (rTMS) is a non-invasive 
technique that selectively modulates the cortical excitability. The Theta Burst 
intermittent (TBi) is a short-lived and very safe stimulation protocol that can 
be an alternative to the conventional treatments. 
Objective: To analyze the therapeutic effect of rTMS-TBi on spasticity of the 
lower limbs by clinical and neurophysiological parameters in MS patients 
refractory to other treatments. 
Methods: Patients with relapsing-remitting MS were randomized to 
experimental/control groups. 
Treatment protocol: 10 sessions of rTMS-TBi applied to the contralateral 
motor cortex (to the most spastic lower limb) for 2 weeks. 
The spasticity degree was assessed using: direct clinical parameters 
(Modified Ashworth Scale, MAS), indirect clinical parameters [Penn Spam 
Frequency Scale (PSFS), plantar support, time to traverse 8 metres (Hauser 
index)], and neurophysiological parameters (H/M ratio). Data were analysed 
at pre-treatment, at the end of 10 rTMS sessions, and 2 weeks later. 
Results: 11 patients were studied (6 experimental and 5 placebo). One of 
the 6 patients on treatment improved the plantar support (from plantigrade to 
heel-toe at the end of the treatment and 2 weeks later). MAS improved in 5 
patients and remained at 2 weeks (in 2 of the 3 muscles analyzed). PSFS 
improved in 3 patients but the effect was not sustained. The walking speed 
improved in all 6 patients at the end of the treatment and 2 weeks later. 
In the control group, 1 patient improved the plantar support, 2 the walking 
speed and 3 the PSFS. All of them showed improvement in at least one 
muscle group. 
The H/M ratio showed an improvement in the experimental group which 
remained stable until the last day, however, this was not observed in the 
control group. 
Conclusions: There were no significant differences according to clinical 
parameters between experimental and control groups. The 
neurophysiological analysis (ratio H/M) revealed a sustained improvement in 
the experimental group. 
Due to the small sample size, the study results were not conclusive. 
Nothing to disclose 
 
